SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LCTX

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE: LCTX · Real-Time Price · USD
Healthcare · Biotechnology
$0.80-$0.12 (-13.07%)
 
Market cap
$201M
Insider Score
Analyst consensus
Insider Score
76/ 100
LCTX Insider Score
Bullish

1 qualifying trade · 1 insider · $17.10K bought in the last 90 days

LCTX Income Statement

Fiscal PeriodQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Period EndingSep 30, 2026Jun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025
Revenue$1.43 M$1.07 M$1.73 M$6.61 M$3.68 M—
Revenue Growth (YoY)-61.04 %—————
Cost of Revenue$5.00 K$0.00$0.00$66.00 K$5.00 K—
Gross Profit$1.43 M$1.07 M$1.73 M$6.54 M$3.68 M—
SG&A Expense$4.92 M$5.22 M$5.08 M$4.85 M$4.19 M—
R&D Expense$3.82 M$4.77 M$4.23 M$8.24 M$3.27 M—
Operating Expenses$8.74 M$9.99 M$9.32 M$13.09 M$7.46 M—
Operating Income-$7.31 M-$8.92 M-$7.59 M-$6.55 M-$3.79 M—
Pretax Income$4.71 M$1.54 M-$4.79 M-$4.39 M-$29.75 M—
Tax Provision$484.00 K———$0.00—
Net Income$4.23 M$1.48 M-$4.81 M$851.00 K-$29.78 M—
EPS (Basic)-$0.02$0.01-$0.02—-$0.13-$0.13
EPS (Diluted)-$0.03$0.01-$0.03—-$0.13-$0.13
Shares Outstanding252.91 M249.50 M245.03 M—228.85 M228.36 M

Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.
Lineage Cell Therapeutics, Inc. (LCTX) Financials: Revenue, Earnings & Balance Sheet | InsiderBuying.com